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Experimental Procedures 
General. Unless otherwise noted, all chemicals and reagents for chemical 
reactions were obtained from commercial suppliers (Sigma-Aldrich, VWR, Alfa 
Aesar) and used without further purification. Silica gel chromatography 
purifications were carried out using AMD Silica Gel 60, 230-400 mesh. 1H and 
13C spectra were recorded on a Varian Inova 500 MHz instrument in DMSO, and 
are referenced to the residual solvent peak. Synthetic reactions were monitored 
using thin layer chromatography (Merck 60 gel plates) using an UV-lamp for 
visualization.  
Chromatography. Analytical high-performance liquid chromatrography (HPLC) 
was carried out using an Agilent 1200 series. Total turnover numbers were 
determined on a Kromasil 100 C18 column (Peeke Scientific 4.6 x 50 mm, 5 μm) 
column measured against an 1,3,5-trimethoxybenzene as an internal standard 
with H2O and acetonitrile as the mobile phase. Regioselectivity was determined 
on an Agilent XDB-C18 column (9.4 x 250 mm, 5 μm) at 230 nm with H2O and 
methanol as the mobile phase. Analytical chiral HPLC was conducted using a 
supercritical fluid chromatography (SFC) system with isopropanol and liquid CO2 
as the mobile phase. Chiral OD-H and AD-H columns were used to separate the 
sultam enantiomers (4.6 x 150 mm, 5 μm). Sultam standards were prepared as 
reported.1  
Cloning and site-directed mutagenesis. pET22b(+) was used as a cloning and 
expression vector for all enzymes described in this study. Site-directed 
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mutagenesis was performed using a modified QuikChangeTM mutagenesis 
protocol. The PCR products were gel purified, digested with DpnI, repaired using 
Gibson MixTM, and directed transformed into E. coli strain BL21(DE3). 
Determination of P450 concentration. Concentration of P450/P411 enzymes 
was determined from ferrous carbon monoxide binding difference spectra using 
previously reported extinction coefficients for cysteine-ligated ( = 91,000 M-1cm-
1) and serine-ligated enzymes ( = 103,000 M-1 cm-1). 
Protein expression and purification. Enzymes used in purified protein 
experiments were expressed in BL21(DE3) E. coli cultures transformed with 
plasmid encoding P450 or P411 variants. Expression and purification was 
performed as described except that the shake rate was lowered to 130 RPM 
during expression.2 Following expression, cells were pelleted and frozen at -20 
°C. For purification, frozen cells were resuspended in buffer A (20 mM tris, 20 
mM imidazole, 100 mM NaCl, pH 7.5, 4 mL/g of cell wet weight) and disrupted by 
sonication (2 x 1 min, output control 5, 50% duty cycle; Sonicator 3000, Misonix, 
Inc.). To pellet insoluble material, lysates were centrifuged at 24,000 x g for 0.5 h 
at 4 °C. Proteins were expressed in a construct containing a 6x-His tag and were 
consequently purified using a nickel NTA column (5 mL HisTrap HP, GE 
Healthcare, Piscataway, NJ) using an AKTAxpress purifier FPLC system (GE 
healthcare). P450 or P411 enzymes were then eluted on a linear gradient from 
100% buffer A 0% buffer B (20 mM tris, 300 mM imidazole, 100 mM NaCl, pH 
7.5) to 100 % buffer B over 10 column volumes (P450/P411 enzymes elute at 
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around 80 mM imidazole). Fractions containing P450 or P411 enzymes were 
pooled, concentrated, and subjected to three exchanges of phosphate buffer (0.1 
M KPi pH 8.0) to remove excess salt and imidazole. Concentrated proteins were 
aliquoted, flash-frozen on powdered dry ice, and stored at -20 °C until later use.  
Reaction screening in 96-well plate format. Site-saturation libraries were 
generated by employing the “22c-trick” method.3 E. coli libraries were generated 
and culture in 200 μL of LBAMP and stored as glycerol stocks at -80 ºC in 96-well 
plates. 50 μL of the preculture was transferred to a 1200 μL of Hyperbroth using 
a multichannel pipette. The cultures were incubated at 37 ºC, 200 rpm, 80% 
humidity until the OD600 = 4 (approx. 2.5 hours). The plates were cooled on ice 
for 30 minutes before expression was induced (0.5 mM IPTG, 1mM Ala final 
concentration. Expression was conducted at 20 ºC, 180 rpm, 20 h. The cells 
were pelleted (4000g, 10 min, 4 ºC) and the 96-well plate was transferred to an 
anaerobic chamber. The pellets were resuspended in 300 μL argon sparged 
reaction buffer (4:1 M9-N/glucose (250 mM)). GOX solution (10x, 40 μL/well) was 
added to each well followed by azide 1 (100 mM, 10 μL/well). The plate was 
sealed with aluminum sealing tape, removed from the anaerobic chamber, and 
shaken at 40 rpm. After 12 hours, the seal was removed and 500 μL of 
acetonitrile and 10 μL of standard (10 mM) were added to each well. The plate 
was vortexed and centrifuged (4000g, 30 minutes) and 500 μL aliquots were 
transferred to a shallow-well plate for analysis by HPLC. 
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Typical procedure for small-scale amination bioconversions under 
anaerobic conditions using whole cells. E. coli BL21(DE3) cells containing 
P450 or P411 enzymes were expressed and resuspended to an OD600=30 in M9-
N), and then degassed by sparging with argon in a sealed 6 mL crimp vial for at 
least 30 mintues. Separately, glucose (250 mM dissolved in 1X M9-N, 40 μL, or 
multiples thereof) was degassed by sparging with argon for at least five minutes. 
The oxygen quenching mixture (40 μL) was added to a 2 mL crimp vial 
containing stir bars. All solutions were uncapped and transferred into an 
anaerobic chamber. Resuspended cells (300 μL) were added to the vial 
containing the oxygen quenching mixture, followed by glucose (50 μL), and 
substrate (100 mM arylsulfonyl azide, 10 μL in DMSO). The vial was sealed, 
removed from the anaerobic chamber and stirred at room temperature for 8h. 
The reactions were quenched by adding acetonitrile (450 μL) and internal 
standard (1,3,5 trimethoxybenzene (10 mM in DMSO). The mixture was then 
transferred to a microcentrifuge tube and centrifuged at 14,000 rpm for 10 
minutes. The solution was transferred to an HPLC vial and analyzed by HPLC for 
yield and regioselectivity. For chiral HPLC the reactions were extracted with ethyl 
acetate, dried and resuspended in DMSO (100 μL) and then C18 purified to 
isolate the major regioisomer. The purified material was dried, resuspended in 
acetonitrile, and injected onto the chiral HPLC system for analysis.  
Determination of initial rates. All initial rate experiments were set up in an 
anaerobic chamber. Four 2-ml vials were charged with a stir bar, GOX 10x (40 
μL), glucose (250 mM, 40 μL), NADPH (20 mM, 40 μL), and KPi (pH = 8.0, 0.1 
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M, 260 μL). The vials were sealed with a silicon crimp cap and removed from the 
anaerobic chamber. The reactions were placed on a stir plate and charged with 
azide 1 or azide 1’ (100 mM, 10 μL). The reactions were quenched at 2-3 minute 
intervals over 8-12 minutes by decapping and adding acetone (500 μL) and 
internal standard (1,3,5-trimethoxybenzene 10 mM, 10 μL) . After 5 minutes of 
stirring, the reaction mixtures were transferred to 1.8 mL tubes, which were 
vortexed and centrifuged (14,000 x g, 10 min). The supernatant was transferred 
to a vial for analysis by HPLC. TTNs were plotted as a function of time for the 
proteo- and deutero-substrate and compared to determine the 1H-KIE for 
P411BM3-CIS-T438S-I263F and P411BM3-T268A-F87A (Figures S2 and S3).  
Crystallization, data collection, and structure determination. The heme 
domain of P411BM3-CIS-T438S-I263F was purified, flash frozen in liquid N2, and 
stored at -80 °C until crystallization. Sitting drop vapor diffusion experiments were 
performed by generating a 1:1 mixture of protein stock (12 mg/mL in 0.1 M KPi, 
pH = 8.0) and well solution in a 96-well sitting-drop plate with a final drop volume 
of 0.4 µL and a reservoir volume of 400 µL. Crystals grew over 5-10 days in 0.1 
M Tris/HCl (pH = 7.0), 2.0 M ammonium sulfate, 0.2 M lithium sulfate. Crystals 
were cryoprotected by immersion into well solution with 20% glycerol before 
being flash-frozen in liquid N2. Diffraction data were collected on the Stanford 
Synchrotron Radiation Laboratory Beamline 12-2. Data were processed using 
XDS in the spacegroup P42212 to 2.66 Å resolution.
4 
The structure of P411BM3-CIS-T438S-I263F was solved by molecular 
replacement using the Phaser program,5 as implemented in CCP4,6 using the 
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P411BM3-CIS structure [PDB ID: 4H23] as the search model. Model building 
was performed in Coot and restrained refinement in Refmac5.7 Model quality was 
assessed with the MolProbity online server.8 TLS operators were included in the 
last round of refinement.9 Crystallographic and model statistics are described in 
Table S1. 
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Table S1. Data processing and refinement statistics (PDB=4WG2) 
 
 
Data processing P411BM3-CIS-T438S-I263F 
Wavelength  
Spacegroup P42212 
Unit cell dimensions  = 90° 
    a = b , c             206.9 , 119.39 
    α = β = γ 90 
Beamline SSRL 12-2 
Wavelength 0.9795 Å 
Resolution (Å) 39.1 – 2.66 
Last bin (Å) 2.8 – 2.66 
Number of Observations 1,031,477 
Completeness (%) 100 (100) 
Rmeas (%) 0.25 (2.1) 
Rpim (%) 0.067 (0.550) 
I/σI 11.0 (1.44) 
CC1/2 0.996 (0.534) 
Redundancy 13.8 (14.5) 
  
Refinement   
Number of reflections 70732 
Number of atoms 10947 
Last bin (Å) 2.73 – 2.66 
Rwork 19.7 (34.7) 
Rfree 23.5 (37.5) 
Average B factor (Å2) 36.2 
Ramachandran Plot  
     Most favored (%) 96.4 
     Allowed (%) 99.9 
     Outliers (%) 0.1 
Values in parenthesis are for the highest resolution shell 
Rmerge is Σ|Io – I| / ΣIo , where Io is the intensity of an individual reflection, and I is the mean 
intensity for multiply recorded reflections 
Rpim is 1/(N-1) Σ|Io – I| / ΣIo, where N is the number of observations for a given reflection 
Rwork is ||Fo – Fc|| / Fo, where Fo is an observed amplitude and Fc a calculated amplitude; 
Rfree is the same statistic calculated over a 5.1% subset of the data that has not been included 
during refinement. 
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Sultams 2 and 3 were previously reported by Katsuki.10 
 
 
 
 
 
ethyl 3-methyl-3,4-dihydro-2H-benzo[e][1,2]thiazine-7-carboxylate 1,1-
dioxide (9) 
 
1H 500 MHz (DMSO d6): 8.17 (d, 1H, J=1.8 Hz), 8.06 (d, 1H, J=1.8, 8.2 Hz), 7.53 
(m, 2H), 4.34 (q, 2H, J=7.25 Hz), 3.83 (m, 1H), 3.06 (dd, 1H, J=17.6, 3.7 Hz), 
2.79 (dd, 1H, J=17.6, 11.4 Hz), 1.34 (3H, t, J=7.1 Hz), 1.28 (3H, d, J=6.6 Hz).  
 
13C 125 MHz (DMSO d6): 164.4, 141.4, 137.9, 131.8, 130.7, 128.9, 123.7, 61.3, 
48.6, 34.9, 21.0, 14.1.  
 
 
 
 
ethyl 3-ethyl-2,3-dihydrobenzo[d]isothiazole-6-carboxylate 1,1-dioxide (10) 
 
1H 500 MHz (DMSO d6): 8.23 (dd, 1H, J=8.1, 1.5 Hz), 8.20 (d, 1H, J=1.5 Hz), 
8.16 (d, 1H, J=4.2 Hz), 7.77 (d, 1H, J=8.1 Hz), 4.72 (ap p, 1H, J=4.0 Hz), 4.37 (q, 
2H, J=7.1 Hz), 1.97 (m, 1H), 1.68 (m, 1H), 1.35 (t, 3H, J=7.1 Hz), 0.90 (t, 3H, 
J=7.3 Hz). 
 
13C 125 MHz (DMSO d6): 164.3, 145.3, 136.9, 133.3, 131.1, 125.7, 121.1, 61.5, 
58.2, 27.9, 14.1, 9.8.  
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TABLE S2: Mutations (relative to wild-type P450BM3) in enzymes used in this 
study. 
 
Enzyme Mutations relative to wild-type P450BM3 
P450BM3 None 
P411BM3-T268A C400S-T268A 
P450BM3-CIS V78A, F87V, P142S, T175I, A184V, S226R, 
H236Q, E252G, T268A, A290V, L353V, I366V, 
E442K 
P411BM3-CIS P450BM3-CIS C400S 
P411BM3-H2-5-F10 P411BM3-CIS L75A, I263A, L437A 
P411BM3-H2-4-D4 P411BM3-CIS M177A, L181A, L437A 
P411BM3-H2-A10 P411BM3-CIS L75A, L181A 
P411BM3-CIS-T438S P411BM3-CIS T438S 
P411BM3-CIS-T438S-I263F P411BM3-CIS T438S, I263F 
P411BM3-CIS-T438S-I263F-A268T P411BM3-CIS T438S, I263F, A268T 
P450BM3-CIS-T438S-I263F P450BM3-CIS T438S, I263F 
P411BM3-MAN1-T268A V78A, F81L, A82T, F87A, P142S, T175I, A184V, 
F205C, S226R, H236Q, E252G, R255S, A290V, 
L353V, C400S  
P411BM3-MAN1-T268A-M263I V78L, F87A, P142S, T175I, A184T, F205C, 
S226R, H236Q, E252G, R255S, A290V, G315S, 
A330V, L353V, T268A, C400S 
P411BM3-T268A-F87A C400S-T268A-F87A 
P411BM3-T268A-F87V C400S-T268A-F87V 
P411BM3-CIS-T438S-I263F-F87A P411BM3-CIS T438S, I263F 
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TABLE S3: Mass Balance of Reactions 
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TABLE S4: Control Experiments.  
 
 
 
Conditions TTN (2 + 3) 
CS (P411BM3-CIS-T438S-I263F) 361 
Empty Vector 0 
CS + CO 0 
Hemin + Na2S2O4 0 
Hemin + Na2S2O4 + BSA 0 
 
Conditions for whole-cell catalysis – Cells resuspended to OD600 = 30 in M9-N 
(300 μL), GOX mixture (10x 14,000U catalase/1,000U glucose oxidase per mL) 
(40 μL), 250 mM Glucose (50 uL), 100 mM azide 1 (10 μL).  
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Table S5: Results with reactions run with purified protein and in lyophilized whole 
cells. 
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FIGURE S1. P411BM3-CIS-T438S-I263F (blue) and P411BM3-CIS-T438S (green) 
overlaid with key residues displayed and labeled. 
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Figure S2. (Left) P411BM3-CIS-T438S-I263F (blue) occluding C16-C18 of PAM. 
(Right) and P450BM3 (green) containing PAM.  
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Figure S3. Initial Rate Plots of Azide 1 (blue diamonds) and Azide 1’ (red 
squares) with P411BM3-CIS-T438S-I263F. Each point is an average of 3 runs  
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Figure S4. Initial Rate Plots of Azide 1 (blue diamonds) and Azide 1’ (red 
squares) with P411BM3-T268A-F87A. Each point is an average of 3 runs  
 
 
 
 
 
 
 
 
 
  
Proteo 
 
y = 0.51x 
R² = 0.96 
Deutero 
 
y = 0.17x 
R² = 0.88 
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12 14
T
o
ta
l 
T
u
rn
o
v
e
r 
N
u
m
b
e
rs
 (
T
T
N
) 
Time (m) 
KIE = 3.0 ± 0.5     
  S18  
Figure S5. Docking Model of Sultam 3 covalently bound to heme with P411BM3-
CIS-T438S-I263F. Docking done using Autodock Vina.11 
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Figure S6. Regioselectivity for Conversion of Azide 1 to Sultams 2 and 3 
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Figure S7. Regioselectivity for Conversion of Azide 4 to Sultams 5 and 6 
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Figure S8. Regioselectivity for Conversion of Azide 7 to Sultams 8 and 9 
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Figure S9: Enantioselectivity Sultam 2 
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Figure S10: Enantioselectivity Sultam 3 
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Figure S11: Enantioselectivity Sultam 4 
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Figure S12: Enantioselectivity Sultam 5 
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Figure S13: Enantioselectivity Sultam 8 
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Figure S14: Enantioselectivity Sultam 9 
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Figure S15: Co-Injection HPLC Traces for Sultam 2 and 3 
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Figure S16: Co-Injection HPLC Traces for Sultam 5 and 6 
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Figure S17: Co-Injection HPLC Traces for Sultam 8 and 9 
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Figure S18: LC-MS Traces for Sultams 2 + 3 
 
Predicted M+H = 240.1 
Observed M+H = 240.1 
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Figure S19: LC-MS Traces for Sultams 5 + 6  
 
Predicted M+H = 268.1 
Observed M+H = 268.1 
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Figure S20: LC-MS Traces for Sultams 8 + 9  
 
Predicted M+H = 270.1 
Observed M+H = 270.1 
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Figure S21: Calibration Curves for Sultam Products  
 
Sultam 2 and 3 
 
Sultam 5 and 6 
 
 
Sultam 8 and 9 
 
y = 1.07x 
R² = 0.96 
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9
M
o
la
r 
R
a
ti
o
 
HPLC Ratio 
y = 1.53x 
R² = 0.9961 
0
1
2
3
4
5
6
7
0 1 2 3 4 5
M
o
la
r 
R
a
ti
o
 
HPLC Ratio 
y = 1.40x 
R² = 0.98 
0
1
2
3
4
5
6
0 0.5 1 1.5 2 2.5 3 3.5 4
M
o
la
r 
R
a
ti
o
 
HPLC Ratio 
  S35  
                                                        
1
  Ruppel, J. C.; Kamble, R. M.; Zhang, X. P. Org. Lett. 2007, 9, 4889-4892. 
2
  Coelho, P. S.; Brustad, E. M.; Kannan, A.; Arnold, F. H. Science 2013, 339, 307. 
3
  S. Kille, C. G. Acevedo-Rocha, L. P. Parra, Z.-G Zhang, D. J. Opperman, M. T. Reetz, J. P. 
Acevedo, ACS Synth. Biol. 2013, 2, 83–92.  
4
  Kabsch, W. Acta Cryst. 2010, D66, 125. 
5
  McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J.  
J. Appl. Cryst. 2007, 40, 658. 
6
  Bailey, S. Acta Cryst. 1994, D50, 760. 
7
  (a) Emsley, P.; Cowtan, K.  Acta Cryst. 2004, D60, 2126. (b) Winn, M. D.; Murshudov, G. N.; 
Papiz, M. Z. Macromolecular Crystallography, Pt D 2003, 374, 300. 
8
  Chen, V. B. ; Arendall III, W. B.; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; 
Murray, L. W.; Richardson, J. S.; Richardson, D. C.  Acta Cryst. 2010, D66, 12. 
9
  Painter, J.; Merritt, E. A. J. Appl. Cryst. 2006, 39, 109. 
10
  Ichinose, M.; Suematsu, H.; Yasutomi, Y.; Nishioka, Y.; Uchida, T.; Katsuki, T. Angew. Chem. 
Int. Ed. 2011, 50, 9884-9887.  
11
  Trott, O.; Olson, J. A. J. Comp. Chem. 2010, 31, 455.  
